Trial Profile
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs CYAD 01 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms DEPLETHINK
- Sponsors Celyad Oncology
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 03 Apr 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 08 Dec 2020 Preliminary results of both THINK and DEPLETHINK clinical studies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology